|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||42.61 - 44.67|
|52 Week Range||38.06 - 82.35|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||255.57|
|Earnings Date||Nov 14, 2017 - Nov 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.75|
How far off is Surmodics, Inc. (NASDAQ:SRDX) from its intrinsic value? Using the most recent financial data, we'll...
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 third quarter ended June 30, 2019, and updated its financial outlook for fiscal 2019.
If you're interested in Surmodics, Inc. (NASDAQ:SRDX), then you might want to consider its beta (a measure of share...
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2019 conference call on Wednesday, July 31, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the third quarter fiscal 2019 financial results and accomplishments.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies 2019 Healthcare Conference in New York City on Tuesday, June 4, 2019, at 10:30 a.m. ET (9:30 a.m. CT). A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com and clicking on the webcast icon.
Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.